TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8887592

Group type: EXPERIMENTAL
Intervention: Index hospital stay
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Mortality rates
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Cost of index hospital stay
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Length of index hospital stay
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Readmission rates
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Quality of life at 6 months
Number of subjects: 1016

Group type: EXPERIMENTAL
Intervention: Survival time
Number of subjects: 1016
Study: 1291567

Group type: EXPERIMENTAL
Intervention: Subzonal insemination (SUZI); 11 cycles in the first part of the study.
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Subzonal insemination (SUZI); 35 cycles in the second part of the study.
Number of subjects: 27

Group type: COMPARATOR
Intervention: Classic IVF insemination; 11 cycles in the first part of the study.
Number of subjects: 27
Study: 3881006

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 20 mg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of nifedipine and isosorbide dinitrate
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 31637821

Group type: EXPERIMENTAL
Intervention: Intervention: Six-monthly repeat home-based HIV counselling and testing (RHBCT) and referral of PLHIV to local HIV clinics, ART initiated regardless of CD4 count.
Number of subjects: 8563

Group type: COMPARATOR
Intervention: Control: ART initiated according to national guidelines.
Number of subjects: 8563
Study: 30499484

Group type: EXPERIMENTAL
Intervention: Osteopathic treatment combined with pharmacotherapy
Number of subjects: 106

Group type: COMPARATOR
Intervention: Medicamentous treatment alone (Control)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Pharmacotherapy and massage (Comparison group)
Number of subjects: 106
Study: 26808991

Group type: EXPERIMENTAL
Intervention: Primary PCI with stenting and distal protection device (for both genders)
Number of subjects: 501
Study: 25344024

Group type: EXPERIMENTAL
Intervention: Extra-depth footwear
Number of subjects: 59
Study: 22305197

Group type: EXPERIMENTAL
Intervention: 100 mg oral thiamine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 500 mg oral thiamine hydrochloride
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1500 mg oral thiamine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 20663072

Group type: EXPERIMENTAL
Intervention: Iterative cardiac output measurement using inert gas rebreathing (IGR)
Number of subjects: 24
Study: 17621459

Group type: EXPERIMENTAL
Intervention: Darunavir (DRV/r)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Lamivudine (3TC)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Abacavir (ABC)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Enfuvirtide (T-20)
Number of subjects: 4000
Study: 15866997

Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 483

Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 483

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 483
Study: 10999733

Group type: EXPERIMENTAL
Intervention: Octreotide 200 microg three times daily
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Octreotide 500 microg three times daily
Number of subjects: 84

Group type: COMPARATOR
Intervention: 5-fluorouracil with or without leucovorin
Number of subjects: 84
Study: 9126802

Group type: EXPERIMENTAL
Intervention: Silymarin 600 mg per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 60
Study: 1493839

Group type: EXPERIMENTAL
Intervention: Salmeterol 50 micrograms
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 micrograms
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3981952

Group type: EXPERIMENTAL
Intervention: Quantitative chloride titrator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative chloride titrator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (common antihypertensive medications)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Additional chloride intake (potassium chloride)
Number of subjects: 0
Study: 30743107

Group type: EXPERIMENTAL
Intervention: PGF2α (AL mares)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Saline solution (control mares)
Number of subjects: 7
Study: 29421015

Group type: EXPERIMENTAL
Intervention: Pre-hospital ticagrelor
Number of subjects: 1856

Group type: COMPARATOR
Intervention: In-hospital ticagrelor
Number of subjects: 1856
Study: 26390014

Group type: EXPERIMENTAL
Intervention: Memory Specificity Training (MeST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study: 23945716

Group type: EXPERIMENTAL
Intervention: Dried sea buckthorn berries (SBs)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil (SBo)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sea buckthorn phenolics ethanol extract mixed with maltodextrin (SBe+MD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Frozen bilberries
Number of subjects: 80
Study: 20647562

Group type: EXPERIMENTAL
Intervention: TAXUS Liberté PES
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: JACTAX HD (9.2 microg each of polymer and paclitaxel per 16-mm stent)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: JACTAX LD (5 microg each of polymer and paclitaxel)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: JACTAX HD
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: JACTAX LD
Number of subjects: 60
Study: 18230234

Group type: EXPERIMENTAL
Intervention: Expressive writing (20-minute sessions for 4 weeks)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Neutral writing (20-minute sessions for 4 weeks)
Number of subjects: 88
Study: 16633921

Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control
Number of subjects: 2000
Study: 13678973

Group type: EXPERIMENTAL
Intervention: Nevirapine (200 mg at labour onset and 2mg/kg for babies within 72 h of birth)
Number of subjects: 645

Group type: COMPARATOR
Intervention: Zidovudine (600 mg orally at labour onset and 300 mg every 3 h until delivery, and 4 mg/kg orally twice daily for babies for 7 days)
Number of subjects: 645
Study: 11075769

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide plus cyclosporin (50 mg/kg daily for 4 days)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional immunosuppression with ATG plus cyclosporin (40 mg/kg daily for 4 days)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: High-dose cyclophosphamide
Number of subjects: 31
Study: 8883753

Group type: EXPERIMENTAL
Intervention: Atad Ripener Device
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 intracervical gel (0.5 mg)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 intravaginal pessary (3 mg)
Number of subjects: 114
Study: 1422319

Group type: EXPERIMENTAL
Intervention: Ipriflavone 600 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ipriflavone 1200 mg/day
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Ipriflavone 1200/600 mg/day sequence
Number of subjects: 16
Study: 3081211

Group type: EXPERIMENTAL
Intervention: Early active mobilisation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Standard treatment (rest and immobilisation with a soft cervical collar)
Number of subjects: 61
Study: 29411360

Group type: EXPERIMENTAL
Intervention: Group cognitive rehabilitation (CR) therapy consisting of eight 2-hour sessions over a 4-week period.
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Group cognitive rehabilitation (CR) therapy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (non-therapeutic group sessions)
Number of subjects: 34
Study: 27173861

Group type: EXPERIMENTAL
Intervention: Planned single zotarolimus-eluting stent strategy
Number of subjects: 450

Group type: COMPARATOR
Intervention: Planned dual zotarolimus-eluting stent strategy
Number of subjects: 450
Study: 24589784

Group type: EXPERIMENTAL
Intervention: Transverse Acetabular Ligament (TAL) group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Freehand group
Number of subjects: 80
Study: 22785608

Group type: EXPERIMENTAL
Intervention: Statin therapy for 8 months
Number of subjects: 119
Study: 20163570

Group type: EXPERIMENTAL
Intervention: Continuous smoking
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Smoking cessation with transdermal nicotine patch
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo patch (control)
Number of subjects: 78
Study: 18315976

Group type: EXPERIMENTAL
Intervention: Weightbearing CT scan
Number of subjects: 48
Study: 19552488

Group type: EXPERIMENTAL
Intervention: Blonanserin 2.5 mg
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Blonanserin 5 mg
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Blonanserin 10 mg
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 307
Study: 16314787

Group type: EXPERIMENTAL
Intervention: SRL-CsA-ST (triple therapy)
Number of subjects: 430

Group type: COMPARATOR
Intervention: SRL-ST (sirolimus and steroids only)
Number of subjects: 430
Study: 11421499

Group type: EXPERIMENTAL
Intervention: Continuous oxygen therapy
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Oxygen therapy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Nocturnal oxygen therapy
Number of subjects: 5

Group type: COMPARATOR
Intervention: Long-term oxygen therapy
Number of subjects: 5
Study: 9469531

Group type: EXPERIMENTAL
Intervention: Combination of 1 mg/ml morphine and 3 mg/ml ketorolac
Number of subjects: 42

Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Combination of half-doses of morphine and ketorolac
Number of subjects: 42
Study: 8203838

Group type: EXPERIMENTAL
Intervention: ofloxacin plus roxithromycin (150 mg twice daily)
Number of subjects: 131

Group type: COMPARATOR
Intervention: ofloxacin alone
Number of subjects: 131
Study: 3441016

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12225330

Group type: EXPERIMENTAL
Intervention: Interferon plus ribavirin (combination therapy)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Interferon alone (monotherapy)
Number of subjects: 41
Study: 29310619

Group type: EXPERIMENTAL
Intervention: Financial incentive scheme for breastfeeding (vouchers)
Number of subjects: 35
Study: 27769840

Group type: EXPERIMENTAL
Intervention: 2-step orthosis
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional orthosis
Number of subjects: 44
Study: 24903787

Group type: EXPERIMENTAL
Intervention: Isoniazid (INH) preventive therapy
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Acetylisoniazid (AcINH) detection
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Arkansas test at 24 h
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Arkansas test at 48 h
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Arkansas test at 72 h
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: INH or AcINH detection at 24 h
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: INH or AcINH detection at 48 h
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: INH or AcINH detection at 72 h
Number of subjects: 31
Study: 22740380

Group type: EXPERIMENTAL
Intervention: golimumab 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: golimumab 100 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 20338901

Group type: EXPERIMENTAL
Intervention: Practice Quit Attempt (PQA)
Number of subjects: 750

Group type: EXPERIMENTAL
Intervention: PQA plus Nicotine Replacement Therapy (NRT) sampling
Number of subjects: 750
Study: 18356837

Group type: EXPERIMENTAL
Intervention: 15 mg/day sibutramine for 5 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 15986749

Group type: EXPERIMENTAL
Intervention: Surgery to create a pseudomeningomyelocele (artificial CSF reservoir)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Shunt implantation
Number of subjects: 58
Study: 12609786

Group type: EXPERIMENTAL
Intervention: Synergised-pyrethrins thermo-labile foam (F)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Permethrin 5% cream (P)
Number of subjects: 40
Study: 11783169

Group type: EXPERIMENTAL
Intervention: Xianlong Capsule (XLC)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Hydergine (Control)
Number of subjects: 46
Study: 7575756

Group type: EXPERIMENTAL
Intervention: Fosfomycin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Teicoplanin
Number of subjects: 40
Study: 1780723

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infraorbital nerve block (1-1.5 ml) with 1:200,000 epinephrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline injected into the vicinity of the infraorbital foramina (1-1.5 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine infraorbital nerve block
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline injected into the vicinity of the infraorbital foramina
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Both groups (Group A and Group B)
Number of subjects: 60
Study: 7023798

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (COP)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 180
Study: 31402389

Group type: EXPERIMENTAL
Intervention: In-reach rehabilitation in addition to usual ward therapy (n=29)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual ward therapy (n=33)
Number of subjects: 62
Study: 30242334

Group type: EXPERIMENTAL
Intervention: Oral Valproic Acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27448554

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Moderate-Intensity Continuous Training (MICT)
Number of subjects: 28
Study: 25572630

Group type: EXPERIMENTAL
Intervention: Modified-release calcifediol (30, 60, or 90 µg daily for six weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 22885021

Group type: COMPARATOR
Intervention: Control diet (C) consisting of 90% dehydrated lucerne and 10% wheat bran
Number of subjects: 36

Group type: COMPARATOR
Intervention: C with 6% of oil blend (CO)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: C with 2.5% of grape seed extract (GS)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: GS with 6% of oil blend (GSO)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: C with 25% of Cistus ladanifer (CL)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CL with 6% of oil blend (CLO)
Number of subjects: 36
Study: 19910359

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) as an adjunct therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: TENS with narcotic analgesics
Number of subjects: 9

Group type: COMPARATOR
Intervention: TENS alone
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: TENS as an adjunct to other medications
Number of subjects: 9

Group type: COMPARATOR
Intervention: TENS as sole pain-control treatment
Number of subjects: 9
Study: 18602287

Group type: EXPERIMENTAL
Intervention: Night guard intervention (1.5‐mm‐thick ethylene vinyl acetate sheet)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Night guard intervention
Number of subjects: 0
Study: 15751668

Group type: EXPERIMENTAL
Intervention: Reduced prime volume (RPV)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Normal prime volume (NPV)
Number of subjects: 222
Study: 15558302

Group type: EXPERIMENTAL
Intervention: Feedback conditions (individual, groups, or supervisors)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Feedback to supervisors
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no feedback)
Number of subjects: 36
Study: 10962112

Group type: EXPERIMENTAL
Intervention: AIDS patients (n=10)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dilated cardiomyopathy patients (n=10)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy HIV seronegative controls (n=10)
Number of subjects: 30
Study: 9365969

Group type: EXPERIMENTAL
Intervention: 30 mg.kg‐1 propacetamol (15 mg.kg‐1 acetaminophen)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 87
Study: 1411329

Group type: EXPERIMENTAL
Intervention: Standardized maintenance antipsychotic medication for at least 1 year
Number of subjects: 0
Study: 3893694

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered intravenously (30 mg/m2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered orally (30 mg/m2)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) administered intramuscularly (30 mg/m2)
Number of subjects: 6
Study: 31232371

Group type: EXPERIMENTAL
Intervention: Lopinavir-ritonavir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lamivudine
Number of subjects: 0
Study: 29341850

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention (monthly self-management education and quarterly medication management facilitation)
Number of subjects: 182
Study: 27502820

Group type: EXPERIMENTAL
Intervention: Auricular acupressure for five days along with standard medications
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard medications only
Number of subjects: 48
Study: 24588854

Group type: EXPERIMENTAL
Intervention: Subcutaneous human choriogonadotropin alfa followed by intravenous erythropoietin (4000-20,000 IU/dose)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Active treatment cohorts (human choriogonadotropin alfa and erythropoietin)
Number of subjects: 96
Study: 22404250

Group type: EXPERIMENTAL
Intervention: Two-step technique (first treating only reticular veins with a single injection at the base of each cluster of telangiectasias, then successively injecting all remaining telangiectasias a few minutes later)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard technique (successive injections of chromated glycerin mixed with one‐third lidocaine‐epinephrine 1%)
Number of subjects: 53
Study: 19646775

Group type: EXPERIMENTAL
Intervention: Allelic imbalance in sputum and plasma samples
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Allelic imbalance
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: LOH, K-ras mutations, and high levels of free plasma DNA (>5ng/ml plasma)
Number of subjects: 98
Study: 19278086

Group type: EXPERIMENTAL
Intervention: 5% KNO3 gel-to-foam dentifrice, brushed twice daily for either 45 seconds or two minutes for eight weeks, followed by regular dentifrice for four weeks.
Number of subjects: 141
Study: 15641938

Group type: EXPERIMENTAL
Intervention: Hemodialyzed patients (HD)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hemodialyzed patients with ischemic heart disease (IHD)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hemodialyzed patients without ischemic heart disease (IHD)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Carotid IMT
Number of subjects: 21
Study: 12211491

Group type: EXPERIMENTAL
Intervention: SRP + M (scaling and root planing plus subgingival application of minocycline microspheres)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: SRP + M
Number of subjects: 48

Group type: COMPARATOR
Intervention: SRP + V (scaling and root planing plus subgingival application of vehicle control)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 48
Study: 9658750

Group type: EXPERIMENTAL
Intervention: Laser therapy after EMR for elevated type lesions
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Laser therapy after EMR for depressed type lesions
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Additional laser therapy for recurring lesions
Number of subjects: 26
Study: 7852748

Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg daily)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg daily)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 2475589

Group type: EXPERIMENTAL
Intervention: Immediate intensive-induction chemotherapy (arm A) with daunorubicin, vincristine, and cytarabine for remission induction.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Supportive care and mild cytoreductive chemotherapy (arm B) for palliation of leukemia-associated complications.
Number of subjects: 60
Study: 4990

Group type: EXPERIMENTAL
Intervention: 1 mg/kg ketamine
Number of subjects: 26

Group type: COMPARATOR
Intervention: 2 mg/kg ketamine
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both doses of ketamine
Number of subjects: 26
Study: 29116954

Group type: EXPERIMENTAL
Intervention: New methodological tool for CAPA identification
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual adverse event management tools
Number of subjects: 56
Study: 30036394

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Tacrolimus (in vitro)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Belatacept
Number of subjects: 21
Study: 27366745

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 25560342

Group type: EXPERIMENTAL
Intervention: Furazolidone (100 mg PO bid), amoxicillin, and omeprazole
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clarithromycin, amoxicillin, and omeprazole
Number of subjects: 120
Study: 23034420

Group type: EXPERIMENTAL
Intervention: One-stage, full-mouth, ultrasonic debridement (FMUD)
Number of subjects: 31
Study: 19997942

Group type: EXPERIMENTAL
Intervention: Mosapride citrate (15 mg/day) + Omeprazole (20 mg/day) for 12 weeks
Number of subjects: 64
Study: 18418294

Group type: EXPERIMENTAL
Intervention: Terameprocol (90 mg, 2% w/w ointment) administered intravaginally for 7 consecutive days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo (not explicitly detailed in the abstract)
Number of subjects: 14
Study: 16046202

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg preparation
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Lamivudine 150 mg preparation
Number of subjects: 36